Recombinant live attenuated rsv vaccine strain and production method therefor
AssigneeSK Bioscience Co., Ltd.
InventorsKi-weon SEO, Teawoo KWON, Eun-som KIM
Life of this patent
Estimating the term…
Abstract
The present invention provides a recombinant attenuated respiratory syncytial virus (RSV) comprising i) a nucleic acid encoding an F protein of a stabilized pre-fusion respiratory syncytial virus (RSV) or its analogue, variant, or fragment; or ii) a nucleic acid encoding a G protein of vesicular stomatitis Indiana virus (VSV) or its analogue, variant, or fragment, and provides a genome of the recombinant RSV, and a recombinant vector comprising the genome. The recombinant attenuated RSV can be provided as a live vaccine strain which is safe and has excellent stability while maintaining infectiousness.
Claims23
A recombinant attenuated respiratory syncytial virus comprising a nucleic acid encoding an F protein of a stabilized pre-fusion respiratory syncytial virus (RSV) or its analogue, variant, or fragment;
- or
- a nucleic acid encoding a G protein of vesicular stomatitis Indiana virus (VSV) or its analogue, variant, or fragment.
An isolated polynucleotide molecule comprising a nucleic acid encoding an F protein of a stabilized pre-fusion respiratory syncytial virus (RSV) or its analogue, variant, or fragment;
- or
- a nucleic acid encoding a G protein of vesicular stomatitis Indiana virus (VSV) or its analogue, variant, or fragment.
(canceled)
(canceled)
-24. (canceled)
Dependencies are inferred from the claim text.